The EC has granted marketing authorisation for AbbVie’s Tepkinly in combination with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma.

Servier’s head of business development Frederic Scaerou discusses the French company’s recent string of dealmaking.

Fresh with a rebrand, Cyllene will advance gene therapies built on a platform that uses a modified form of the herpes virus for delivery.

Vertex is to acquire Crinetics Pharmaceuticals in a transaction valued at nearly $10bn, or $8.8bn net of estimated cash acquired.

Through predictive modelling, AI supports target identification, prediction of physicochemical properties and formulation strategy selection.

The UK Government has prioritised life science sector growth, but industry members have called for more funding.

Roche’s breast cancer agreement with Astex is one of several oncology deals the Swiss pharma giant has inked in recent years.

Novartis has signed an agreement to purchase Myricx Bio, a UK-based biotechnology company, in a transaction valued at up to $1.5bn.

Besins Healthcare has expanded its pharmaceutical operations with the acquisition of UniD Manufacturing, which specialises in long-acting drug delivery technologies.

Anthropic launches Claude Science as big tech companies increasingly eye expansion in the wider healthcare and life sciences space.

Investors at BIO 2026 say lost life sciences investment has left the US vulnerable while China fosters future big pharma competitors.

Now, her ongoing alliance with a telehealth company may be signifying a broader shift in US healthcare advertising, reflecting a changing of the guard in celebrity endorsements. The 23-time Grand Slam ...